Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:22:36.630Z.
Consensus retrieved: 2026-10-06T15:25:13.945Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:22:36.630Z.
Quote observation: 2026-10-06T18:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64600f38e310d2eb3cd81a0b95bf77f6abd31b9de5548b9cdd3f3c9d46967593
Forward PE Ratio (N/A) = Dated Quote Price ($17.37) / Consensus Forward EPS ($-1.67)
FORWARD PE RATIO
N/A
PROCEPT BioRobotics Corporation
Market Cap
$988.73M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $988.73M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $987.63M | 35.55 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.02M | N/A |
| Vor Biopharma Inc. (VOR)vs › | $1.00B | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 16.49 |
| Savara Inc. (SVRA)vs › | $953.94M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $17.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.67 | $-1.69 – $-1.62 | 9 | n/m |
| 2027-12-31 | $-1.13 | $-1.40 – $-0.87 | 9 | n/m |
| 2028-12-31 | $-0.81 | $-1.00 – $-0.46 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
